Venture capitalist Nicole Vitullo has joined the board of Achillion Pharmaceuticals in connection with her partnership’s recent $50 million private stock placement in the New Haven drug developer, a regulatory filing shows.
Vitullo replaces Michael G. Grey who voluntarily gave up his seat on the board, according to the filing with the Securities and Exchange Commission.
Vitullo is a partner in Domain Associates LLC, which in August led a private investment group that bought about 8 million shares of Achillion common stock and warrants to buy another 2.8 million shares, the filing said.
If the warrants are exercised, Domain will own about 17.7 percent of Achillion, the filing says.
Vitullo was issued options to purchase 25,000 shares of Achillion common tied to the company’s Sept. 30 closing price
Achillion is developing small-molecule drugs for treating blood-borne diseases such as hepatitis C and HIV.
